<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00735</drugbank-id>
  <drugbank-id>APRD01131</drugbank-id>
  <name>Naftifine</name>
  <description>Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.</description>
  <cas-number>65472-88-0</cas-number>
  <unii>4FB1TON47A</unii>
  <average-mass>287.3981</average-mass>
  <monoisotopic-mass>287.167399677</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms &lt;i&gt;Trichophyton rubrum&lt;/i&gt;, &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;, &lt;i&gt;Trichophyton tonsurans&lt;/i&gt; and &lt;i&gt;Epidermophyton floccosum&lt;/i&gt;.</indication>
  <pharmacodynamics>Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative. The following in vitro data are available, but their clinical significance is unknown. Naftifine has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms including &lt;i&gt;Trichophyton rubrum&lt;/i&gt;, &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;, &lt;i&gt;Trichophyton tonsurans&lt;/i&gt;, &lt;i&gt;Epidermophyton floccosum&lt;/i&gt;, and &lt;i&gt;Microsporum canis&lt;/i&gt;, &lt;i&gt;Microsporum audouini&lt;/i&gt;, and &lt;i&gt;Microsporum gypseum&lt;/i&gt;; and fungistatic activity against &lt;i&gt;Candida&lt;/i&gt; species including &lt;i&gt;Candida albicans&lt;/i&gt;. However it is only used to treat the organisms listed in the indications.</pharmacodynamics>
  <mechanism-of-action>Although the exact mechanism of action against fungi is not known, naftifine appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2,3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>Following single topical applications of 3H-labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed.</absorption>
  <half-life>Approximately 2 to 3 days following topical administration.</half-life>
  <protein-binding/>
  <route-of-elimination>Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.</description>
    <direct-parent>Naphthalenes</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Naphthalenes</class>
    <subclass/>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Styrenes</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic homopolycyclic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Naphthalene</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Styrene</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000677</drugbank-id>
      <name>Naftifine Hydrochloride</name>
      <unii>25UR9N9041</unii>
      <cas-number>65473-14-5</cas-number>
      <inchikey>OLUNPKFOFGZHRT-YGCVIUNWSA-N</inchikey>
      <average-mass>323.859</average-mass>
      <monoisotopic-mass>323.144077416</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="german" coder="inn">Naftifin</synonym>
    <synonym language="spanish" coder="inn">Naftifina</synonym>
    <synonym language="english/french" coder="inn">Naftifine</synonym>
    <synonym language="latin" coder="inn">Naftifinum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-1368</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>20 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA206901</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-1362</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA205975</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Renaissance Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40085-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-01</started-marketing-on>
      <ended-marketing-on>2020-04-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>1 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>20 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA206960</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Amneal Pharmaceuticals of New York Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0115-1510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-03-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA206165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Renaissance Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>40085-203</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-02-01</started-marketing-on>
      <ended-marketing-on>2021-08-31</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>20 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftifine Hydrochloride</name>
      <labeller>Taro Pharmaceuticals U.S.A., Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>51672-1376</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>20 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208201</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>DPT Laboratories, Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>63094-4126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-25</started-marketing-on>
      <ended-marketing-on>2010-01-05</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2240</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Merz Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0259-4126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2185</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Merz Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0259-1102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-01</started-marketing-on>
      <ended-marketing-on>2016-12-01</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/2g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Merz Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0259-4770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1990-10-01</started-marketing-on>
      <ended-marketing-on>2016-12-01</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Merz Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0259-1202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-01</started-marketing-on>
      <ended-marketing-on>2016-12-01</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength>2 g/100g</strength>
      <route>Topical</route>
      <fda-application-number>NDA204286</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Sebela Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54766-770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>10 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Sebela Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54766-772</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>2 g/100g</strength>
      <route>Topical</route>
      <fda-application-number>NDA204286</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin</name>
      <labeller>Sebela Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54766-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 mg/2g</strength>
      <route>Topical</route>
      <fda-application-number>NDA019599</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Naftin Crm 1%</name>
      <labeller>Allergan Herbert Skin Care Division Of Allergan Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02011255</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-04</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Naftin Gel 1%</name>
      <labeller>Allergan Herbert Skin Care Division Of Allergan Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02011263</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2011-08-04</ended-marketing-on>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>A Mei</name>
      <company>Shou Chan</company>
    </international-brand>
    <international-brand>
      <name>Ancent</name>
      <company>Yuan Chou</company>
    </international-brand>
    <international-brand>
      <name>Exoderil</name>
      <company>Sandoz</company>
    </international-brand>
    <international-brand>
      <name>Micosona</name>
      <company>Bayer</company>
    </international-brand>
    <international-brand>
      <name>Naftifina</name>
      <company>Antibiotice</company>
    </international-brand>
    <international-brand>
      <name>Suadian</name>
      <company>Sandoz</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftifine Hydrochloride</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin Gel 1%</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
    <mixture>
      <name>Naftin Crm 1%</name>
      <ingredients>Naftifine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>DPT Laboratories Ltd.</name>
      <url>http://www.dptlabs.com</url>
    </packager>
    <packager>
      <name>Merz Pharmaceuticals LLC</name>
      <url>http://www.merz.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Merz pharmaceuticals llc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Naftin 1% cream</description>
      <cost currency="USD">2.45</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Naftin pump 1% cream</description>
      <cost currency="USD">3.2</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Naftin 1% Cream 30 gm Tube</description>
      <cost currency="USD">101.62</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Naftin 1% Gel 40 gm Tube</description>
      <cost currency="USD">147.0</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Naftin 1% Cream 60 gm Tube</description>
      <cost currency="USD">183.77</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Naftin 1% Gel 60 gm Tube</description>
      <cost currency="USD">208.5</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Naftin 1% Cream 90 gm Tube</description>
      <cost currency="USD">248.26</cost>
      <unit>tube</unit>
    </price>
    <price>
      <description>Naftin 1% Gel 90 gm Tube</description>
      <cost currency="USD">290.08</cost>
      <unit>tube</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alkenes</category>
      <mesh-id>D000475</mesh-id>
    </category>
    <category>
      <category>Allyl Compounds</category>
      <mesh-id>D000498</mesh-id>
    </category>
    <category>
      <category>Allylamine Antifungal</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antifungal Agents</category>
      <mesh-id>D000935</mesh-id>
    </category>
    <category>
      <category>Antifungals for Dermatological Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antifungals for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Acyclic</category>
      <mesh-id>D006839</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Yeast and other fungi</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>1 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>20 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>20 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>10 mg/2g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>10 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>10 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>2 g/100g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D01AE22">
      <level code="D01AE">Other antifungals for topical use</level>
      <level code="D01A">ANTIFUNGALS FOR TOPICAL USE</level>
      <level code="D01">ANTIFUNGALS FOR DERMATOLOGICAL USE</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00735.pdf?1265922748</msds>
  <patents>
    <patent>
      <number>9161914</number>
      <country>United States</country>
      <approved>2015-10-20</approved>
      <expires>2033-01-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8778365</number>
      <country>United States</country>
      <approved>2014-07-15</approved>
      <expires>2033-01-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10166206</number>
      <country>United States</country>
      <approved>2019-01-01</approved>
      <expires>2033-01-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10166205</number>
      <country>United States</country>
      <approved>2019-01-01</approved>
      <expires>2033-01-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.96</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-6.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.29e-04 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>methyl(naphthalen-1-ylmethyl)(3-phenylprop-2-en-1-yl)amine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>naftin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>287.3981</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>287.167399677</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN(CC=CC1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C21H21N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C21H21N/c1-22(16-8-11-18-9-3-2-4-10-18)17-20-14-7-13-19-12-5-6-15-21(19)20/h2-15H,16-17H2,1H3/b11-8+</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OZGNYLLQHRPOBR-DHZHZOJOSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>3.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>95.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>34.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>5.4</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>1186</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>7451</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>73342</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504777</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C08071</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>43344</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50170647</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164748617</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000752</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Naftifine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL626</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/naft.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/naftifine-cream.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000577</id>
      <name>Squalene monooxygenase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A5534</ref-id>
            <pubmed-id>8834895</pubmed-id>
            <citation>Favre B, Ryder NS: Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.</citation>
          </article>
          <article>
            <ref-id>A5535</ref-id>
            <pubmed-id>1951574</pubmed-id>
            <citation>Vanden Bossche H, Marichal P: Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.</citation>
          </article>
          <article>
            <ref-id>A5536</ref-id>
            <pubmed-id>12499173</pubmed-id>
            <citation>Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA: Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003 Jan;47(1):82-6.</citation>
          </article>
          <article>
            <ref-id>A5537</ref-id>
            <pubmed-id>3877503</pubmed-id>
            <citation>Ryder NS, Dupont MC: Inhibition of squalene epoxidase by allylamine antimycotic compounds. A comparative study of the fungal and mammalian enzymes. Biochem J. 1985 Sep 15;230(3):765-70.</citation>
          </article>
          <article>
            <ref-id>A5538</ref-id>
            <pubmed-id>1287164</pubmed-id>
            <citation>Ryder NS, Frank I: Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol. 1992;30(6):451-60.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q14534" source="Swiss-Prot">
        <name>Squalene monooxygenase</name>
        <general-function>Squalene monooxygenase activity</general-function>
        <specific-function>Catalyzes the first oxygenation step in sterol biosynthesis and is suggested to be one of the rate-limiting enzymes in this pathway.</specific-function>
        <gene-name>SQLE</gene-name>
        <locus>8q24.1</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions>20-40
61-81
123-143
546-566</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.12</theoretical-pi>
        <molecular-weight>63922.505</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11279</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SQLE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D78130</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2443316</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2433</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14534</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ERG1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.17</synonym>
          <synonym>ERG1</synonym>
          <synonym>SE</synonym>
          <synonym>Squalene epoxidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016141|Squalene monooxygenase
MWTFLGIATFTYFYKKFGDFITLANREVLLCVLVFLSLGLVLSYRCRHRNGGLLGRQQSG
SQFALFSDILSGLPFIGFFWAKSPPESENKEQLEARRRRKGTNISETSLIGTAACTSTSS
QNDPEVIIVGAGVLGSALAAVLSRDGRKVTVIERDLKEPDRIVGEFLQPGGYHVLKDLGL
GDTVEGLDAQVVNGYMIHDQESKSEVQIPYPLSENNQVQSGRAFHHGRFIMSLRKAAMAE
PNAKFIEGVVLQLLEEDDVVMGVQYKDKETGDIKELHAPLTVVADGLFSKFRKSLVSNKV
SVSSHFVGFLMKNAPQFKANHAELILANPSPVLIYQISSSETRVLVDIRGEMPRNLREYM
VEKIYPQIPDHLKEPFLEATDNSHLRSMPASFLPPSSVKKRGVLLLGDAYNMRHPLTGGG
MTVAFKDIKLWRKLLKGIPDLYDDAAIFEAKKSFYWARKTSHSFVVNILAQALYELFSAT
DDSLHQLRKACFLYFKLGGECVAGPVGLLSVLSPNPLVLIGHFFAVAIYAVYFCFKSEPW
ITKPRALLSSGAVLYKACSVIFPLIYSEMKYMVH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016142|Squalene monooxygenase (SQLE)
ATGTGGACTTTTCTGGGCATTGCCACTTTCACCTATTTTTATAAGAAGTTCGGGGACTTC
ATCACTTTGGCCAACAGGGAGGTCCTGTTGTGCGTGCTGGTGTTCCTCTCGCTGGGCCTG
GTGCTCTCCTACCGCTGTCGCCACCGAAACGGGGGTCTCCTCGGGCGCCAGCAGAGCGGC
TCCCAGTTCGCCCTCTTCTCGGATATTCTCTCAGGCCTGCCTTTCATTGGCTTCTTCTGG
GCCAAATCCCCCCCTGAATCAGAAAATAAGGAGCAGCTCGAGGCCAGGAGGCGCAGAAAA
GGAACCAATATTTCAGAAACAAGCTTAATAGGAACAGCTGCCTGTACATCAACATCTTCT
CAGAATGACCCAGAAGTTATCATCGTGGGAGCTGGCGTGCTTGGCTCTGCTTTGGCAGCT
GTGCTTTCCAGAGATGGAAGAAAGGTGACAGTCATTGAGAGAGACTTAAAAGAGCCTGAC
AGAATAGTTGGAGAATTCCTGCAGCCGGGTGGTTATCATGTTCTCAAAGACCTTGGTCTT
GGAGATACAGTGGAAGGTCTTGATGCCCAGGTTGTAAATGGTTACATGATTCATGATCAG
GAAAGCAAATCAGAGGTTCAGATTCCTTACCCTCTGTCAGAAAACAATCAAGTGCAGAGT
GGAAGAGCTTTCCATCACGGAAGATTCATCATGAGTCTCCGGAAAGCAGCTATGGCAGAG
CCCAATGCAAAGTTTATTGAAGGTGTTGTGTTACAGTTATTAGAGGAAGATGATGTTGTG
ATGGGAGTTCAGTACAAGGATAAAGAGACTGGAGATATCAAGGAACTCCATGCTCCACTG
ACTGTTGTTGCAGATGGGCTTTTCTCCAAGTTCAGGAAAAGCCTGGTCTCCAATAAAGTT
TCTGTATCATCTCATTTTGTTGGCTTTCTTATGAAGAATGCACCACAGTTTAAAGCAAAT
CATGCTGAACTTATTTTAGCTAACCCGAGTCCAGTTCTCATCTACCAGATTTCATCCAGT
GAAACTCGAGTACTTGTTGACATTAGAGGAGAAATGCCAAGGAATTTAAGAGAATACATG
GTTGAAAAAATTTACCCACAAATACCTGATCACCTGAAAGAACCATTCTTAGAAGCCACT
GACAATTCTCATCTGAGGTCCATGCCAGCAAGCTTCCTTCCTCCTTCATCAGTGAAGAAA
CGAGGTGTTCTTCTTTTGGGAGACGCATATAATATGAGGCATCCACTTACTGGTGGAGGA
ATGACTGTTGCTTTTAAAGATATAAAACTATGGAGAAAACTGCTAAAGGGTATCCCTGAC
CTTTATGATGATGCAGCTATTTTCGAGGCCAAAAAATCATTTTACTGGGCAAGAAAAACA
TCTCATTCCTTTGTCGTGAATATCCTTGCTCAGGCTCTTTATGAATTATTTTCTGCCACA
GATGATTCCCTGCATCAACTAAGAAAAGCCTGTTTTCTTTATTTCAAACTTGGTGGCGAA
TGTGTTGCGGGTCCTGTTGGGCTGCTTTCTGTATTGTCTCCTAACCCTCTAGTTTTAATT
GGACACTTCTTTGCTGTTGCAATCTATGCCGTGTATTTTTGCTTTAAGTCAGAACCTTGG
ATTACAAAACCTCGAGCCCTTCTCAGTAGTGGTGCTGTATTGTACAAAGCGTGTTCTGTA
ATATTTCCTCTAATTTACTCAGAAATGAAGTATATGGTTCATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF08491</identifier>
            <name>SE</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>flavin adenine dinucleotide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>squalene monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular aromatic compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sterol biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>